Biomarker & Precision Medicine US brings together international experts to discuss the latest advancements and tools in biomarker research.

At HBRI we offer bioanalytical and biomarker consultancy for end-to-end specialty laboratory solutions based on a wide range of services.

We have the scientific expertise to identify, design and validate the right assay for your development program across all phases from pre-clinical to phase four and we have the agility to provide customized, fit-for purpose solutions and the scale to deliver on a global basis.

Don't miss our presentation

Date & Time:  Tuesday, 28 October, 2:05pm – 2:30pm

Speaker: Marie Gerus-Durand, R&D Manager, Histopathology, HBRI

Presentation: Enhancing Breast Cancer Treatment Decisions with Artificial Intelligence: A Reliable Approach to Ki-67 Scoring

Ki-67 is a key breast cancer biomarker in guiding treatment for HR+, HER2- patients. Yet, no consensus exists for its scoring, mainly due to pathologists’ variability.

A HBRI conducted comparative study positioned AI as a powerful tool to support breast cancer treatment orientation.

Visit us at booth #16

Our team will be on the ground and will be happy to discuss your upcoming needs and explore how our bioanalytical and biomarker consultancy for end-to-end specialty laboratory solutions can advance your research.

Our team would be delighted to speak with you to discuss your upcoming needs. Please feel free to arrange a meeting in advance